Evolving Treatment Strategies in Small Cell Lung Cancer - Episode 2

Impact of Disease Staging on Prognosis and Treatment in SCLC

, , ,

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

EP. 1: Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer
Now Viewing
EP. 2: Impact of Disease Staging on Prognosis and Treatment in SCLC
EP. 3: Evolving Role of Biomarkers in SCLC
EP. 4: Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases
EP. 5: Expert Insights on First-line Treatment Strategies in SCLC
EP. 6: CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes
EP. 7: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
EP. 8: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
EP. 9: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%
EP. 10: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
EP. 11: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
EP. 12: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
EP. 13: LAGOON and IMFORTE Trials: Data Updates and Expert Insights
EP. 14: 2L Dosing Considerations and Management Strategies for SCLC
EP. 15: Novel Treatment Approaches for SCLC and Future Perspectives